Drug Profile
Research programme: cancer therapeutics - Hawthorn Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Pittsburgh
- Developer Hawthorn Pharmaceuticals; University of Pittsburgh
- Class Monoclonal antibodies
- Mechanism of Action Cell surface receptor modulators; Proteoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 17 May 2010 Early research in Cancer in USA (unspecified route)